New Mothers Turn to GLP-1 Weight Loss Drugs in Skyrocketing Numbers Postpartum, Research Shows

The landscape of American healthcare and weight management has shifted dramatically over the past several years, marked by a massive surge in the popularity of GLP-1 receptor agonists. This year, the number of United States adults utilizing a GLP-1 medication for weight loss reached an astonishing 11%, meaning that more than one in ten adults are now regularly taking medications such as Ozempic, Wegovy, or Mounjaro.

This remarkable explosion in use has occurred over a surprisingly short period—roughly five years—even though these pharmaceutical options have actually been on the market for more than two decades. The primary driver behind this widespread adoption is simple efficacy: the drugs work. Clinical data indicates that patients lose, on average, between 7% and 11% of their starting weight. Furthermore, a growing body of medical research has revealed a wide array of unexpected ancillary health benefits associated with the treatment. These range from lowering the risk of depression and potentially preventing dementia to reducing the incidence of cancer, heart attacks, and even substance abuse disorders.

Still, the vast majority of patients initiate treatment primarily to shed excess pounds. This trend is particularly pronounced within a specific, fast-growing demographic: new mothers. Recent research highlights a staggering spike in GLP-1 usage among women within six months of giving birth, reflecting broader demographic trends that show women utilize these medications far more frequently than men overall, accounting for up to 70% of all patients on the therapy.

New Moms on the Jab

To better understand demographic shifts in GLP-1 utilization, researchers analyzed roughly one million births and tracked which mothers began taking the medications within the first half-year postpartum. Their findings provide unprecedented insight into how postpartum health challenges intersect with modern blockbuster pharmacology.

Among the cohort examined, new mothers diagnosed with type 2 diabetes accounted for the highest volume of initial prescriptions. Within this specific group, the proportion of women starting a GLP-1 surged from 2.3% in 2018 to 16.9%—translating to roughly one in six patients—by 2025.

However, the data also captured significant increases among women who experienced gestational diabetes, a temporary form of diabetes that develops during pregnancy. For these patients, GLP-1 prescriptions climbed dramatically from 0.4% in 2021 to 2.7% in 2025. Gestational diabetes occurs in approximately 5% to 9% of all pregnancies in the United States and serves as a strong indicator that a mother is at elevated risk of developing permanent type 2 diabetes later in life. Medical literature indicates that as many as 50% to 70% of women who experience gestational diabetes eventually go on to develop type 2 diabetes.

The single fastest-growing segment, however, consisted of women who had been clinically diagnosed as obese or overweight prior to their pregnancy. Among this group, GLP-1 prescriptions skyrocketed from 0.4% in 2021 to 3.9% in 2025, representing nearly a tenfold increase in just four years.

This postpartum surge mirrors the broader evolution of the pharmaceutical market itself. GLP-1 medications were not always approved or widely prescribed for weight management; historically, they were utilized primarily to help diabetic patients regulate their blood sugar levels. That paradigm shifted in 2021 when regulatory approvals expanded to include chronic weight management for individuals struggling with obesity. That policy pivot opened the floodgates for millions of people struggling with weight, kickstarting the unprecedented cultural and medical frenzy observed today.

Losing Pregnancy Weight

Study authors note that just as gestational diabetes carries long-term health implications, the weight gained during pregnancy can prove remarkably stubborn and difficult to shed long after a child is born.

Data indicates that twelve months after giving birth, up to 75% of women weigh more than they did prior to becoming pregnant. This retained postpartum weight contributes significantly to subsequent health complications, including elevated blood pressure, adverse cholesterol levels, and increased insulin resistance. Some longitudinal studies suggest that failing to return to pre-pregnancy weight by one year postpartum serves as a reliable predictor of higher weight markers fifteen years down the line.

Because GLP-1 receptor agonists are generally avoided during pregnancy due to potential risks to fetal development, their usage naturally remains on hold until after delivery. This clinical constraint helps explain why prescription rates spike so sharply within the crucial six-month window following birth. Researchers emphasize that these medications can serve as an important clinical tool to help manage the long-term metabolic risks associated with postpartum weight retention and diabetes prevention.

Nevertheless, because new mothers are initiating treatment so soon after giving birth, medical researchers and healthcare professionals are calling for more extensive study into how GLP-1 medications might interact with breastfeeding. While preliminary data from at least one study showed that GLP-1 compounds were not detectable in breast milk, clinical experts continue to advise caution. Due to the limited long-term safety data in nursing infants, many healthcare providers currently advise against using the weight-loss drugs while breastfeeding.